Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity (PubMed:21985311). The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both (PubMed:21985311, PubMed:32961270). Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome.
The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization
Interacts with MARK1, MARK2, MARK3 and MARK4 (PubMed:23666762). Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated (PubMed:15953362).
Interacts with FKBP4 (By similarity). Binds to CSNK1D (PubMed:14761950). Interacts with SGK1 (PubMed:16982696).
Interacts with EPM2A; the interaction dephosphorylates MAPT at Ser-396 (PubMed:19542233). Interacts with PIN1 (PubMed:11313338). Interacts with LRRK2 (PubMed:26014385).
Interacts with LRP1, leading to endocytosis; this interaction is reduced in the presence of LRPAP1/RAP (PubMed:32296178)
Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system
The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats
A form of dementia characterized by pathologic finding of frontotemporal lobar degeneration, presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala.
In most cases, protein tau deposits are found in glial cells and/or neurons.
A rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
Characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions.
Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
A syndrome characterized by parkinsonism, tremor, rigidity, dementia, ophthalmoparesis and pyramidal signs. Neurofibrillary degeneration occurs in the hippocampus, basal ganglia and brainstem nuclei.
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to MAPT, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 19
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT02531360 | Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD) | Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies | EARLY_PHASE1 | COMPLETED |
| NCT03510572 | Healthy Volunteer, Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease | Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain | EARLY_PHASE1 | COMPLETED |
| NCT00978536 | Disseminated Sclerosis | A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein). | NA | TERMINATED |
| NCT00094939 | Alzheimer Disease, Dementia | Predictors of Cognitive Decline in Normal Aging | N/A | UNKNOWN |
| NCT02372773 | Familial Frontotemporal Dementia | Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects | N/A | COMPLETED |
| NCT03080051 | Progressive Supranuclear Palsy, Alzheimer Disease, Healthy Volunteers | Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain | EARLY_PHASE1 | COMPLETED |
| NCT03186989 | Mild Alzheimer's Disease | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease | PHASE1 | COMPLETED |
| NCT04318626 | Post-stroke Cognitive Impairment, Neuroinflammation | The Influence of [18F]PMPBB3 and [18F]THK5351 PET Distribution Patterns on Post-stroke Cognitive Impairment | PHASE2 | UNKNOWN |
| NCT07244211 | Femoral Neck Fractures | MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP) | NA | RECRUITING |
| NCT04309253 | Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia | The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy | PHASE2 | UNKNOWN |